Xenon Pharmaceuticals Inc. (XENE)Healthcare | Biotechnology | Burnaby, Canada | NasdaqGM
35.52 USD
-0.29
(-0.809%) ⇩
(Oct. 13, 2026, 10:07 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:33 a.m. EDT
The investment case here is driven entirely by a binary catalyst: the upcoming top-line data from the Phase 3 X-TOLE2 study. While the company sits on a fortress balance sheet with negligible debt and massive cash reserves, it is currently burning cash, which is standard for biotechs but limits the runway if the trial fails. The stock has already rallied significantly on previous positive data, yet analysts remain bullish, suggesting the market believes the asset class is undervalued relative to the potential upside. However, the statistical forecasting models are completely useless here, showing zero confidence due to the extreme volatility inherent in pre-catalyst biotech stocks. This is not a stock for steady income or predictable growth; it is a high-risk, high-reward speculative play where the entire thesis hinges on a single future event. Investors are clearly betting big on a moonshot outcome, creating a volatile trading environment where the next few weeks will define the next few years. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.082653 |
| AutoARIMA | 0.085917 |
| AutoETS | 0.085918 |
| AutoTheta | 0.147609 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 23.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 17.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.517 |
| Market Cap | 3,439,772,160 |
| Forward P/E | -7.52 |
| Beta | 0.60 |
| Website | https://www.xenon-pharma.com |
As of Oct. 10, 2026, 4:33 a.m. EDT: Speculators are positioning for a binary event with heavy call volume at distant strikes ($70, $90) and significant put protection at near-term levels ($37.5, $40). The massive implied volatility spike at the $55 strike suggests a specific catalyst is priced in, while the overwhelming open interest in out-of-the-money calls indicates a speculative bet on a major trial readout or commercial milestone rather than steady accumulation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.11732805 |
| Address1 | 200-3650 Gilmore Way |
| All Time High | 72.66 |
| All Time Low | 2.1 |
| Ask | 82.15 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,154,470 |
| Average Daily Volume3 Month | 1,406,071 |
| Average Volume | 1,406,071 |
| Average Volume10Days | 2,154,470 |
| Beta | 0.604 |
| Bid | 47.27 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 12.841 |
| City | Burnaby |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 35.52 |
| Current Ratio | 21.015 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 35.9024 |
| Day Low | 35.36 |
| Debt To Equity | 0.517 |
| Display Name | Xenon Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | -439,188,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.792 |
| Enterprise Value | 2,543,587,840 |
| Eps Current Year | -4.62818 |
| Eps Forward | -4.72489 |
| Eps Trailing Twelve Months | -4.74 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 53.0874 |
| Fifty Day Average Change | -17.567398 |
| Fifty Day Average Change Percent | -0.33091465 |
| Fifty Two Week Change Percent | -11.732805 |
| Fifty Two Week High | 72.66 |
| Fifty Two Week High Change | -37.140003 |
| Fifty Two Week High Change Percent | -0.51114786 |
| Fifty Two Week Low | 35.06 |
| Fifty Two Week Low Change | 0.45999908 |
| Fifty Two Week Low Change Percent | 0.013120338 |
| Fifty Two Week Range | 35.06 - 72.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,197,800,000 |
| Float Shares | 90,904,114 |
| Forward Eps | -4.72489 |
| Forward P E | -7.517635 |
| Free Cashflow | -203,547,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 358 |
| Fullday Change | -0.29000092 |
| Fullday Change Percent | -0.80915433 |
| Fullday Price | 35.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -352,484,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00159 |
| Held Percent Institutions | 1.0732399 |
| Implied Shares Outstanding | 96,840,432 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. |
| Long Name | Xenon Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 3,439,772,160 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_565718 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -409,195,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,543,391,406 |
| Number Of Analyst Opinions | 18 |
| Open | 35.65 |
| Operating Cashflow | -337,520,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 604 484 3300 |
| Previous Close | 35.81 |
| Price Eps Current Year | -7.674723 |
| Price Hint | 2 |
| Price To Book | 2.7661397 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 20.714 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26316 |
| Region | US |
| Regular Market Change | -0.29000092 |
| Regular Market Change Percent | -0.80915433 |
| Regular Market Day High | 35.9024 |
| Regular Market Day Low | 35.36 |
| Regular Market Day Range | 35.36 - 35.9024 |
| Regular Market Open | 35.65 |
| Regular Market Previous Close | 35.81 |
| Regular Market Price | 35.52 |
| Regular Market Time | 1,791,900,446 |
| Regular Market Volume | 65,311 |
| Return On Assets | -0.28019 |
| Return On Equity | -0.43616 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 96,840,432 |
| Shares Percent Shares Out | 0.0624 |
| Shares Short | 6,041,487 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,344,135 |
| Short Name | Xenon Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0625 |
| Short Ratio | 2.69 |
| Source Interval | 15 |
| State | BC |
| Symbol | XENE |
| Target High Price | 90.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 72.425 |
| Target Median Price | 73.5 |
| Total Cash | 930,686,016 |
| Total Cash Per Share | 9.611 |
| Total Debt | 6,418,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 52.869576 |
| Two Hundred Day Average Change | -17.349575 |
| Two Hundred Day Average Change Percent | -0.32815802 |
| Type Disp | Equity |
| Volume | 65,311 |
| Website | https://www.xenon-pharma.com |
| Zip | V5G 4W8 |